

**CFH Antibody (Center)**  
**Affinity Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP10942c****Specification**

---

**CFH Antibody (Center) - Product Information**

Application	IF, WB, IHC-P,E
Primary Accession	<a href="#">P08603</a>
Other Accession	<a href="#">NP_000177.2</a>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	751-780

**CFH Antibody (Center) - Additional Information****Gene ID** 3075**Other Names**

Complement factor H, H factor 1, CFH, HF, HF1, HF2

**Target/Specificity**

This CFH antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 751-780 amino acids of human CFH.

**Dilution**

IF~~1:25

WB~~1:2000

IHC-P~~1:50~100

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

CFH Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

**CFH Antibody (Center) - Protein Information****Name** CFH**Synonyms** HF, HF1, HF2

**Function** Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces (PubMed:[21285368](#), PubMed:[25402769](#)). Accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, thus preventing local formation of more C3b, the central player of the complement amplification loop (PubMed:[19503104](#), PubMed:[26700768](#)). As a cofactor of the serine protease factor I, CFH also regulates proteolytic degradation of already-deposited C3b (PubMed:[23332154](#), PubMed:[18252712](#), PubMed:[28671664](#)). In addition, mediates several cellular responses through interaction with specific receptors. For example, interacts with CR3/ITGAM receptor and thereby mediates the adhesion of human neutrophils to different pathogens. In turn, these pathogens are phagocytosed and destroyed (PubMed:[9558116](#), PubMed:[20008295](#)).

#### Cellular Location

Secreted.

#### Tissue Location


Expressed in the retinal pigment epithelium (at protein level) (PubMed:[25136834](#)). CFH is one of the most abundant complement components in blood where the liver is the major source of CFH protein in vivo. In addition, CFH is secreted by additional cell types including monocytes, fibroblasts, or endothelial cells (PubMed:[6444659](#), PubMed:[2968404](#), PubMed:[2139673](#), PubMed:[25136834](#)).

#### CFH Antibody (Center) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


#### CFH Antibody (Center) - Images




Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HepG2 (human liver hepatocellular carcinoma cell line) cells labeling CFH with AP10942c at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG (1583138) secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on HepG2 cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin (OI17558410) at 1/100 dilution (red). The nuclear counter stain is DAPI (blue).




Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HepG2 (human liver hepatocellular carcinoma cell line) cells labeling CFH with AP10942c at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG (1583138) secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on HepG2 cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin (OI17558410) at 1/100 dilution (red). The nuclear counter stain is DAPI (blue).



All lanes : Anti-CFH Antibody (Center) at 1:2000 dilution Lane 1: human lung lysate Lane 2: human plasma lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 139 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



All lanes : Anti-CFH Antibody (Center) at 1:2000 dilution Lane 1: Human plasma lysate Lane 2: Human kidney lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 139 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



CFH antibody (Center) (Cat. #AP10942c) immunohistochemistry analysis in formalin fixed and paraffin embedded human hepatocarcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the CFH antibody (Center) for immunohistochemistry. Clinical relevance has not been evaluated.

### CFH Antibody (Center) - Background

This gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

### CFH Antibody (Center) - References

Dieterich, R., et al. Infect. Immun. 78(11):4467-4476(2010)  
Sofat, R., et al. Atherosclerosis 213(1):184-190(2010)

Davila, S., et al. Nat. Genet. 42(9):772-776(2010)  
Scambi, C., et al. PLoS ONE 5 (8), E12162 (2010) :  
Bunkenborg, J., et al. Proteomics 4(2):454-465(2004)